{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-040917","form_type":"8-K","ticker":"AVAH","cik":"0001832332","company_name":"Aveanna Healthcare Holdings, Inc.","filed_at":"2023-08-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:35.574372+00:00","generated_at":"2026-06-11T19:03:35.286469+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Aveanna Q2 revenue up 6.5% to $472M; raises full-year guidance","bullets":["Revenue $471.9M (+6.5% YoY); net income $25.6M vs loss $473.9M (absence of $470.2M goodwill impairment).","Adjusted EBITDA $35.8M (-3.2% YoY, +25.6% seq.); margin 7.6% vs 8.3% prior year.","Full-year 2023 revenue guidance raised to $1,850M-$1,860M; Adj. EBITDA guidance $132M-$135M.","PDS segment revenue up $29.6M; HHH segment down $6.0M; Medical Solutions up $5.3M.","Cash $28M; revolver undrawn with $162M capacity; securitization facility extended to July 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-040917","json":"https://secwatch.observer/filing/0000950170-23-040917.json","markdown":"https://secwatch.observer/filing/0000950170-23-040917.md","text":"https://secwatch.observer/filing/0000950170-23-040917.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1832332/000095017023040917/0000950170-23-040917-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1832332/000095017023040917/avah-20230810.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T19:03:35.286469+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"aa311fd9a36ac1dff353491428db9c4ce4e0abab","claim":"Aveanna Healthcare Holdings, Inc. reported three and six-month periods ended July 1, 2023 results: revenue $471.9 million, net income $25.6 million, EPS $0.13. Guidance raised.","evidence_excerpt":"Revenue was $471.9 million, a 6.5% increase over the prior year o Gross margin increased 7.0% to $155.3 million, compared to Q2 2022 • Net income was $25.6 million, compared to net loss of $473.9 million in the comparable prior year period o Adjusted EBITDA was $35.8 million, a sequential increase of 25.6% and a 3.2% decrease as compared to the prior year • Full year 2023 revenue guidance raised to a range of $1,850 million to $1,860 million o Full year 2023 Adjusted EBITDA guidance raised to a range of $132 million to $135 million","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1832332/000095017023040917/0000950170-23-040917-index.htm","confidence":1.0,"family_label":"Earnings Releases","details":[{"label":"Period","value":"three and six-month periods ended July 1, 2023"},{"label":"Revenue","value":"$471.9 million"},{"label":"Net income","value":"$25.6 million"},{"label":"EPS","value":"$0.13"},{"label":"Guidance","value":"raised"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}